MedWatch

Olympus upgrades guidance following better-than-expected report

Japanese Olympus has closed this year's Q1 so well that the medtech firm, whose advisors include former Ambu CEO Lars Marcher, upgrades its guidance for the whole year.

Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

Thursday morning, Japanese medical equipment manufacturer Olympus presented its first quarter financial result, which shows better sales than expected, which is also demonstrated in the firm's operating earnings.

Olympus, whose advisors include former Ambu CEO Lars Marcher, is upgrading its guidance for the whole year.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs